Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE
NCT06122610Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copper Cu 64 dotatate and lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN), sponsored by University of Wisconsin–Madison. Primary endpoint: Compare pre-therapy and post-therapy voxel-based dosimetry estimates. Started Mar 2025; status: completed.
02
Drugs
copper Cu 64 dotatatelutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06122610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122610.